Polarean Imaging Plc

("Polarean" or the "Company")

Strategic Review and Consideration of AIM Listing Status

Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology company and global leader in functional lung imaging using hyperpolarised Xenon MRI, announces that its Board of Directors is undertaking a strategic review of the Company's future direction and organisational structure.  

The Board recognises that the UK public market environment for small-cap MedTech companies remains highly challenging, characterised by persistent undervaluation, limited liquidity, and the ongoing costs associated with maintaining a public listing. With shares frequently trading below their intrinsic value and market activity remaining subdued, investors continue to face difficulties executing trades efficiently. At the same time, the Company requires additional capital to advance the development and commercialisation of its technology.

In light of these factors, the Board is evaluating all available options to maximise long-term shareholder value, including identifying opportunities to further reduce operational costs while maintaining strict financial discipline. Among the options under consideration is the potential cancellation of the admission of the Company's ordinary shares to trading on AIM ("Cancellation"). After careful deliberation, the Board believes that, under certain circumstances, a transition to a private company structure could reduce operational expenses, provide greater strategic flexibility, and broaden access to capital on more favourable terms.

No decision has been made at this stage. Should the Board determine that pursuing a Cancellation and re-registration of the Company as a private company is in the best interests of shareholders, a detailed circular setting out the background, rationale, and implications of such a proposal will be sent to shareholders. Any Cancellation would require the approval of not less than 75 percent of votes cast by shareholders at a duly convened general meeting, in accordance with Rule 41 of the AIM Rules for Companies.

The Company remains committed to advancing its mission of revolutionising pulmonary medicine through Xenon MRI and to continuing commercial growth while this review is ongoing. A further announcement will be made if and when the Board decides to proceed with any specific course of action.

Enquiries:

About Polarean

Polarean is a revenue-generating medical imaging technology company revolutionising pulmonary medicine through direct visualisation of lung function by introducing the power and safety of MRI to the respiratory healthcare community. This community is in desperate need of modern solutions to accurately assess lung function. The Company strives to optimise lung health and prevent avoidable loss by illuminating hidden disease, addressing the global unmet medical needs of more than 500 million patients worldwide suffering from chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now FDA-approved in the United States. Polarean is dedicated to researching, developing, and commercialising innovative imaging solutions with its non-invasive and radiation-free pulmonary functional MRI platform. This comprehensive drug-device platform encompasses the proprietary Xenon gas blend, gas hyperpolarisation system, as well as software and accessories, facilitating fully integrated modern respiratory imaging operations. Founded in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is committed to increasing global awareness of and broad access to its XENOVIEW MRI technology platform.

For the latest news and information about Polarean, please visit www.polarean.com.